| 摘要 |
This invention provides methods and compositions, most preferably pharmaceutical compositions, for treating salt-sensitive hypertension through the inhibition of certain enzymes in the beta-adrenergic pathway that are involved in the regulation of the secretion of water and sodium. These enzymes are cyclic nucleotide phosphodiesterases (PDE) that selectively hydrolyze the second messenger cAMP and, therefore, down-regulate beta-adrenergic signaling. Specifically provided are methods and pharmaceutical compositions for treating salt-sensitive hypertension by inhibiting certain members of the PDE4 family of cyclic nucleotide phosphodiesterases, particularly members of the PDE4B and PDE4D sub-families and, more particularly, the PDE4B1 and PDE4D5 isotypes thereof.
|
